《大行》招商证券升巨子生物(02367.HK)目标价至69元 评级“买入”

阿斯达克财经
31 Mar

招商证券发表研究报告指,即使巨子生物(02367.HK) 今年1月已经上调去年下半年业绩指引,其去年下半年销售额及净利润仍较市场预期高出8%及5%,该行认为这势头源于可复美(COMFY)线上销售强劲。展望2025年,管理层预计销售额将录得25%至28%增长。

该行指,将集团今年收入预测上调5.6%,并下调2025财年至2026财年营运利润预测,同时将其目标价由60元上调至69元,其评级为“买入”。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10